The healthcare problem we solve
The promise of modern medicine is immense, yet critical challenges persist in delivering truly personalized care:
The Efficacy Gap: Matching Patients to Effective Therapies
A critical challenge in modern medicine is the ‘efficacy gap.’ Even for advanced treatments in complex areas like immune-mediated diseases and oncology, response rates often hit a therapeutic ceiling, with maximum 30-40% of patients experiencing therapeutic response. This means many individuals may not receive the life-changing impact a therapy can offer, underscoring the urgent, unmet need to accurately identify the right therapy for the right patient.
Deep Biological Complexity
The efficacy gap directly stems from vast biological complexity. Hundreds of interacting cell types across diverse tissues drive individual disease courses and treatment responses, particularly in immune-related conditions and cancer. Truly understanding these intricate mechanisms to develop accurate diagnostic or predictive assays requires high-resolution measurements at the cellular and molecular level.
The Untapped Potential of Big Data
While cutting-edge technologies now generate a ‘tsunami’ of the necessary high-resolution biological data, this presents its own significant hurdle. The sheer volume, dimensionality, and complexity of this ‘big data’ can overwhelm conventional analytical tools, often failing to extract clear, actionable intelligence. There is a profound need for advanced analytical capabilities and tailored AI-driven approaches to navigate this data deluge and provide the precise answers required to guide truly personalized treatment decisions.
12 successful discovery projects
1000+ single cell samples analyzed
50 Billion data points
The Scailyte Solution: Deep Insights turned into Clinical Breakthroughs
The full promise of powerful medicines, such as immuno-therapies, is often unrealized due to highly variable patient responses and an incomplete understanding of the factors defining these responses. This results in a trial-and-error approach to treatment selection, often causing unnecessary patient suffering, poor outcomes, and massive healthcare costs. Scailyte directly confronts this critical healthcare and societal challenge, guided by two key principles: deep biological understanding and patient impact. Our integrated approach combines multiple data modalities and our cutting-edge AI into a translational research platform that yields impactful precision medicine products. As pioneers in single-cell data discovery since 2017, we have developed a pipeline of diagnostic and predictive biomarkers tackling some of the most pressing clinical and therapeutic hurdles, often in novel ways.
Foundation: Unparalleled Data
We harness the power of high-resolution, multimodal omics data. Our expertise lies in generating and integrating these rich datasets, often leveraging our unique clinical network access or working with partner-provided data, to create an unparalleled foundation for discovering the subtle signals that fuel our diagnostic and CDx pipeline.
ScaiVision: Our Proprietary Explainable AI Engine
At the heart of our capability is ScaiVision, our proprietary and best-in-class explainable AI platform. It expertly navigates the ‘noise’ within these massive datasets, pinpointing critical signals and biological drivers that conventional methods often miss, providing the engine for our innovative product development.
Translating Discovery into Our Clinical Solutions
We decipher intricate disease biology, understand drug mechanisms of action (MoA) and resistance, and develop precise predictive biomarkers for patient sub-population identification and treatment response. These discoveries are then rigorously translated by our team into robust, clinically validated assays and decision support tools designed to empower clinicians and transform patient outcomes.
Why Scailyte? Beyond Conventional AI: Our Definitive Advantage in Precision Medicine.
Accelerated Path to Our Clinical Solutions:
Our advanced AI and streamlined processes dramatically reduce timelines from complex multimodal data to validated biological insights. This speed enables Scailyte to rapidly advance our pipeline of innovative diagnostic and CDx solutions from concept to clinical readiness. With continuous automation and technological evolution, our R&D timelines are getting shorter and shorter, while our capacity to run multiple clinical programs in parallel is scaling up.
Superior Discovery Power for Our Pipeline:
ScaiVision identifies elusive disease drivers and highly predictive signatures with unparalleled sensitivity and specificity. This exceptional discovery power allows Scailyte to pioneer novel diagnostic approaches and identify unique therapeutic opportunities that fuel our pipeline of precision medicine products.
From a Black Box to Biological Truth:
Our Explainable AI delivers fully transparent and interpretable results. This provides deep biological understanding that empowers Scailyte's confident, data-driven decisions and defines clear pathways for translating our internal discoveries into simplified clinical assays for diagnostics and CDx solutions.
Proven Performance, Unwavering Reliability:
Leveraging our pioneering expertise in AI-driven single-cell discovery, Scailyte's platform delivers highly robust and reproducible findings. This proven performance and unwavering reliability are foundational to developing our pipeline of trusted, high-impact clinical solutions.
Exclusive Data Access: Fueling Our Next-Generation Diagnostics & CDx
Through our established clinical network, Scailyte gains privileged access to unique patient cohorts and deep multimodal real-world data, especially in oncology and immunology. This direct line to clinical reality fuels the discovery and validation of highly relevant and impactful signatures that form the core of our diagnostic and CDx pipeline.
Scailyte is committed to developing next-generation precision medicine products that break the therapeutic ceiling and enable high efficacy treatments for all patients. Our discovery pipeline features promising diagnostic and CDx candidates, each born from deep biological understanding derived from our unique data access and the analytical power of ScaiVision AI. These solutions aim to transform patient outcomes in challenging therapeutic areas by paving the way for more personalized and effective healthcare.
Partner Testimonials
Meghan Verschoor
Associate Director, Data Science in Clinical and Translational Medicine at Turnstone Biologics
“Our team is very impressed with the level of attention to detail and domain knowledge that the Scailyte team brings to our project. We’re excited to continue working with your team!”
Thomas Mehrling
MD PhD, CEO of MaxiVAX
“Scailyte has been instrumental in analyzing phase IIa clinical single-arm trial data of our most advanced development program. Scailyte’s scientific expertise, communication style and agility are commendable”
Prof. Dr Michael Mueller
Leading Clinician in Women’s Health & Scientific Advisor
“Our current collaboration with Scailyte in the field of women’s health is a truly innovative approach. We are integrating cutting edge technologies to develop biomarkers that will be the basis for impactful diagnostic solutions.”
Pascal Koenig
Entrepreneur & Chairman of the Board of Directors
“As the co-founder and former CEO of Ava Women, I have experienced the power that big datasets have on the healthcare industry. Scailyte’s mission, proven technology and strong expertise have convinced me to join the team. I am delighted to contribute and assist in bringing Scailyte’s solution to patients around the world.”
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
01
/04
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
02
/04
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
03
/04
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
04
/04
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...